Clinical trials: Hepatitis C
Drug Use, Hepatitis C
Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA
The results of the GX device are equivalent to standard venous blood sampling. With this study we are going to determine the prevalence in drug users with difficult venous access.
- Trial name
- NCT04717856
- Testing
- screening: HCV RNA test and risk factors questionaire
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Hepatitis C
Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)
The QuickStart study aims to assess the impact of three models of HCV care on HCV treatment uptake and cure among people who inject drugs.
- Trial name
- NCT05016609
- Testing
- OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead)
- Where
- 6 sites in Australia
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C, Drug Use
Future Destinations: Journeys Towards Citizenship
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), if left untreated it can lead to chronic liver disease, cirrhosis and cancer.
- Trial name
- NCT04159545
- Testing
- Qualitative and quantitative interviews
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Hepatitis C
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at…
- Trial name
- NCT02278419
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Hepatitis C
Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin
The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.
- Trial name
- NCT02104843
- Testing
- Daclatasvir, Asunaprevir and BMS-791325 FDC, BMS-791325, Rosuvastatin
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Hepatitis C
Tajik Migrant Health Education Study
This study will test the efficacy of a peer-education prevention intervention to reduce risky drug, alcohol, and sexual behaviors among male Tajik labor migrants who inject drugs (MWID) while working in Moscow.
- Conditions
- HIV Infections, Hepatitis C, Risky Health Behavior, Risk Reduction Behavior
- Trial name
- NCT04853394
- Testing
- MASLIHAT, TANSIHAT
- Where
- Russia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Insulin Resistance, Metabolic Syndrome x
Insulin Resistance Study
The purpose of this study is to evaluate how often patients with hepatitis C infection have abnormalities of sugar and fat utilization.
- Trial name
- IR (NCT00614757)
- Testing
- N-acetylcysteine 20% 4ml, N-acetylcysteine 20% in 4 ml
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Midwest Biomedical Research
Hepatitis C
HCV Test and Treat Utilizing Simplified HCV Patient Education
The study hypothesis is that the test and treat model utilizing video-based patient education will have higher rates of hepatitis C virus (HCV) treatment initiation and treatment completion.
- Trial name
- NCT05582681
- Testing
- Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
HIV Infection, Syphilis
Strengthening, Guidance, Health, Empowerment
The goal of this interventional study is to describe the care pathway following the use of an innovative home self-sampling method for the screening of six sexually transmitted infections (STIs) among sex workers met during…
- Conditions
- HIV Infection, Syphilis, Gonorrhea Infection, Chlamydia Infection
- Trial name
- ROSE (NCT07788599)
- Testing
- Self-sampling for six sexually transmitted infections
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Hepatitis C, Chronic
Drug-drug Interaction of BI 201335 and Microgynon
This study will investigate possible effect of multiple oral doses of BI 201335 on the steady state pharmacokinetics of ethinylestradiol and levonogestrel
- Trial name
- NCT01570244
- Testing
- levonorgestrel, Ethinylestradiol, BI 201335
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV
Male Engagement in PMTCT Services
The study employs a quasi-experimental design in 8 public health centers in southwest Uganda offering care and treatment (C\&T) services.
- Trial name
- NCT01903889
- Testing
- clinic based intervention, clinic and community based intervention
- Where
- 7 sites in Uganda
- Volunteers
- 3,806 people, healthy volunteers welcome
- Sponsor
- FHI 360
Hepatic Failure, Hepatic Impairment
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
The objective was to determine if hepatitis C virus (HCV) infection or mild to severe hepatic impairment (Child-Pugh Classes A, B, and C) altered the PK of buprenorphine, norbuprenorphine, or naloxone.
- Conditions
- Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
- Trial name
- NCT01846455
- Testing
- 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Hepatitis C, Chronic, Healthy Volunteer
A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo controlled, 3 part study will assess the safety, tolerability and pharmacokinetics of RO5303253 in healthy volunteers and patients with chronic hepatitis C genotype 1.
- Trial name
- NCT01181024
- Testing
- RO5303253
- Where
- New Zealand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche